Can an Ozonated Extra-Virgin Olive Oil Gel Improve Gum Disease Treatment?

Study Overview

The paper, “Clinical and Microbiological Study on Local Application of an Ozonated Olive Oil Gel in the Periodontal Pockets: A Randomized Double-Blind Trial,” was published in the Journal of Clinical Medicine in 2025 by Roberta Grassi and colleagues. It was a single-center, double-blind randomized clinical and microbiological study conducted at the University of Bari in Southern Italy.

The trial enrolled adults with stage II, III, or IV periodontitis. Twenty-seven patients with a mean age of 48 ± 7 years were included, and 40 periodontal pockets were analyzed over 6 months. Participants needed probing pocket depth of at least 4 mm at two or more sites, no recent antibiotics or corticosteroids, no smoking, and no known allergy to ozonated olive-oil components.

Everyone received conventional scaling and root planing, the mechanical deep-cleaning procedure used to remove plaque and calculus below the gumline. The test group then received approximately 1-1.5 mL of activated ozonated extra-virgin olive oil gel applied subgingivally and interproximally using a syringe. The placebo group received a visually and texturally similar gel without the active ozonated EVOO complex. Both the operator and outcome assessor were blinded.

The clinical endpoints were probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), and bleeding on probing (BOP), recorded at baseline, 3 months, and 6 months. The microbiological endpoint was bacterial copy count measured by real-time PCR for six key periodontal pathogens: Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, and Campylobacter rectus.

Key Findings: The Actual Numbers

The clinical signal was consistent. In the placebo group, probing pocket depth moved from 4.2 mm at baseline to 3.9 mm at 6 months. In the AOEOO group, it moved from 4.3 mm to 3.2 mm. The between-group comparison was already significant at 3 months (p = 0.04) and stronger at 6 months (p = 0.001).

Clinical attachment level followed the same pattern. Placebo improved from 4.9 to 4.6 mm, while AOEOO improved from 5.1 to 3.6 mm, with inter-group p = 0.03 at 3 months and p = 0.001 at 6 months. Plaque index improved from 1.6 to 1.4 with placebo, compared with 1.6 to 0.9 with AOEOO; bleeding on probing improved from 0.6 to 0.5 with placebo, compared with 0.7 to 0.3 with AOEOO.

The microbial data are the most persuasive part of the paper. Total bacterial load in the AOEOO group fell from 16,410,000 ± 20,500,000 to 9,750,000 ± 12,800,000 copy counts, a 40.6% reduction (p = 0.03). In the placebo group, bacterial load increased non-significantly from 16,082,024 ± 21,044,706 to 17,638,983 ± 28,769,618 (p = 0.61). Final between-group difference: p = 0.04.

Specific pathogens also dropped sharply in the AOEOO group: A. actinomycetemcomitans by 63.8% (p = 0.02), P. gingivalis by 76.2% (p = 0.01), T. denticola by 98.7% (p = 0.002), T. forsythia by 86.5% (p = 0.01), F. nucleatum by 64.7% (p = 0.03), and C. rectus by 97.7% (p = 0.001). No adverse effects were recorded.

Mechanism: Why an Ozonated Olive-Oil Gel Might Work

This is not the same mechanism as eating extra virgin olive oil. The biological action is local. Ozone is a strong oxidant that can disrupt microbial membranes, increase permeability, damage bacterial enzymes and nucleic acids, and reduce viable biofilm organisms. When ozone is incorporated into olive oil, the oil acts as a stabilizing lipid carrier, generating ozonides, aldehydes, peroxides, and hydroxyperoxides that can be delivered into the pocket in gel form.

Olive oil is not just an inert vehicle. Its monounsaturated fatty acids and phenolic compounds may support tissue compatibility and local anti-inflammatory balance. But the active product here also contained cetylpyridinium chloride, chlorphenesin, collagen, and hyaluronic acid, so the trial cannot isolate “olive oil alone.” The fair interpretation is that an ozonated EVOO-based gel complex improved the local periodontal environment when used after mechanical debridement.

The clinical and microbiological findings fit together. If pathogenic anaerobes are reduced, the pocket may shift away from a tissue-destructive inflammatory state. That can plausibly explain improvements in bleeding, plaque ecology, probing depth, and attachment level. The important point: the gel was used where the problem lives — inside periodontal pockets — rather than relying on systemic effects.

Context: Confirmation or Contradiction?

This trial sits in a small but growing oral-health lane for olive-derived interventions. Recent human studies have tested oleuropein-rich olive leaf extract as an adjunct in periodontitis and ozonated olive-oil oral-care protocols for plaque, bleeding, and pocket depth. The present paper adds value because it includes both clinical indices and PCR-based pathogen counts over 6 months.

It does not prove that ozonated olive oil beats chlorhexidine, antibiotics, or other local periodontal agents. The comparator was placebo gel plus scaling/root planing, not an active antimicrobial standard. But compared with studies that report only pocket depth or bleeding, the pathogen reductions make the biological story more convincing.

The study also reminds us to separate dietary EVOO from topical olive-oil technologies. A high-polyphenol oil on your salad supports cardiometabolic nutrition; an ozonated gel in a periodontal pocket is a local dental product. Same botanical origin, different clinical question.

Limitations

• • Small sample: only 27 patients and 40 periodontal pockets were analyzed, so precision is limited.
• • Single center: results may not generalize across clinics, operators, baseline oral hygiene, or disease severity.
• • Composite active gel: the test product included more than ozonated EVOO, making it impossible to assign the effect to olive oil alone.
• • No active comparator: placebo gel is useful, but clinicians also need comparisons with chlorhexidine, local antibiotics, and other adjuncts.
• • Limited patient-centered outcomes: the authors note no patient-satisfaction assessment, and future work should include comfort, adherence, and real-world acceptability.
• • Inflammatory markers missing: the trial measured pathogens, not local cytokines or inflammatory mediators, which would strengthen the mechanism.

Our Take

This is a promising but early dental-technology study. The effect size is clinically interesting: roughly 1.1 mm pocket-depth improvement from baseline in the AOEOO group versus 0.3 mm with placebo, plus a 1.5 mm attachment-level improvement versus 0.3 mm. In periodontology, millimeters matter.

The microbiology makes it harder to dismiss as measurement noise. Seeing T. denticola fall from 1,230,000 to 15,500 copies and C. rectus from 330,000 to 7,500 copies is a meaningful biological signal, even with the caveat of high baseline variability.

Still, this is not game-changing yet. It needs a larger multicenter trial, standardized pocket-level randomization, active comparators, inflammatory biomarkers, and clearer product-disclosure economics. Our verdict: strong enough to watch closely; not strong enough to make ozonated olive-oil gel a default recommendation outside professional periodontal care.

Reference

Grassi R, Ciccone F, De Falco D, Castaldi M, Agneta MT, Nardi GM, Petruzzi M. Clinical and Microbiological Study on Local Application of an Ozonated Olive Oil Gel in the Periodontal Pockets: A Randomized Double-Blind Trial. Journal of Clinical Medicine. 2025;14(15):5182. doi: 10.3390/jcm14155182. PMID: 40806807. Full text: PMC12347320.